ABSTRACT
Oxidative stress, involved in many diseases, is defined as an impaired balance between reactive oxygen species (ROS) production and antioxidant defences. Antioxidant enzymes such as superoxide dismutase (SOD) play a key role in diminishing oxidative stress. Thus, the removal of ROS by exogenous SODs could be an effective preventive strategy against various diseases. The poor bioavailability of exogenous SODs has been criticized. However, improvements in SOD formulation may overcome this limitation and boost interest in its therapeutic properties. Here, we provide a review of animal and human studies about SODs supplementation in order to evaluate their therapeutic value. Protective effects have been observed against irradiation, carcinogenesis, apoptosis and neurodegeneration. SODs administration has also been reported to alleviate inflammatory, infectious, respiratory, metabolic and cardiovascular diseases and genitourinary and fertility disorders, raising the question of its mechanism of action in these diverse situations. Some authors have shown an increase in endogenous antioxidant enzymes after exogenous SODs administration. The induction of endogenous antioxidant defence and, consequently, a decrease in oxidative stress, could explain all the effects observed. Further investigations need to be carried out to test the hypothesis that SODs supplementation acts by inducing an endogenous antioxidant defence.
Similar content being viewed by others
Abbreviations
- AAPH:
-
Hydrochloride 2,2′-azobis-2-amidinopropane
- AIDS:
-
Acquired immunodeficiency syndrome
- ARE:
-
Antioxidant response element
- CAT:
-
Catalase
- Cu/Zn-SOD:
-
Copper/zinc-superoxide dismutase
- DIVEMA:
-
Divinyl ether and maleic anhydride
- DNA:
-
Deoxyribonucleic acid
- EC-SOD:
-
Extracellular-superoxide dismutase
- Fe-SOD:
-
Iron-superoxide dismutase
- FIV:
-
Feline immunodeficiency virus
- GPx:
-
Glutathione peroxidase
- H2O2 :
-
Hydrogen peroxide
- HIV:
-
Human immunodeficiency virus
- HO°:
-
Hydroxyl radical
- Mn-SOD:
-
Manganese-superoxide dismutase
- Nrf2:
-
Transcription factor nuclear-factor-E2-related factor
- O2°- :
-
Superoxide anion radical
- PEG:
-
Pegylated
- PMA:
-
Phorbol 12-myristate 13-acetate
- ROS:
-
Reactive oxygen species
- SOD:
-
Superoxide dismutase
REFERENCES
Davies KJA. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp. 1995;61:1–31.
Rhee SG. Cell signaling : H2O2, a necessary evil for cell signaling. Science. 2006;312(5782):1882–3.
Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation. 1997;96(10):3264–5.
McCord JM. The evolution of free radicals and oxidative stress. Am J Med. 2000;108:652–9.
Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem. 1995;64:97–112.
Hassan HM, Scandalios JG. Superoxide dismutases in aerobic organism. In: Alscher RG, Cumming JR, editors. Stress Responses in Plants: Adaptation and Acclimation Mechanisms. New York: Wiley-Liss; 1990. p. 175–99.
Nordmann R, Ribière C. Superoxyde dismutases : rôle biologique; espoir thérapeutique ? Cah Nutr Diét. 1991;26(6):398–402.
Beyer W, Imlay J, Fridovich I. Superoxide dismutases. Prog Nucleic Acid Res Mol Biol. 1991;40:221–53.
Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol. 2004;24:1367–73.
Scandalios JG. Molecular genetics of superoxide dismutase in plants. In: Scandalios JG, editor. Oxidative stress and molecular biology of antioxidant defences. Cold Spring Harbor; 1997. P. 527–68.
Muchova J, Sustrova M, Garaiova I, Liptakova A, Blazicek P, Kvasnicka P, et al. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of down syndrome patients. Free Radic Biol Med. 2001;31(4):499–508.
Perluigi M, Butterfield A. Oxidative stress and down syndrome: a route toward Alzheimer-like dementia. Curr Gerontol Geriatr Res. 2012;2012:724904.
Edeas MA, Emerit I, Khalfoun Y, Lazizi Y, Cernjavski L, Levy A, et al. Clastogenic factors in plasma of HIV-1 infected patients activate HIV-1 replication in vitro:inhibition by superoxide dismutase. Free Radic Biol Med. 1997;23(4):571–8.
Epperly MW, Liggitt D, Greenberger JS. Systemic intravenous (IV) as well as local administration of manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) displays no detectable toxicity while offering protection from irradiation-induced damage. Int J Radiat Oncol Biol Phys. 2005;63(2):S487–8.
Greenberger JS, Smith T, Schlesselman JJ, Epperly M. In a mouse model intravenous administration of Mn SOD-PL protects against whole body irradiation. Int J Radiat Oncol Biol Phys. 2007;69(3):S619.
Greenberger JS, Hricisak L, Epperly MW. In a model of irradiation retreatment of the lung (stimulating radiotherapy for lung cancer local recurrence), normal lung tolerance is increased by administration of manganese SOD-PL. Int J Radiat Oncol Biol Phys. 2005;63(2):S475–6.
Rabbani Z, Jackson I, Zhang X, Xu P, Vujaskovic Z. Subcutaneous administration of bovine superoxide dismutase protects lungs from radiation induced lung injury. Int J Radiat Oncol Biol Phys. 2010;78(3):S39–40.
Epperly MW, Kagan VE, Sikora CA, Gretton JE, Defilippi SJ, Bar-Sagi D, et al. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation. Int J Cancer. 2001;96:221–31.
Nie Y, Epperly M, Shen H, Greenberger JS. Intraesophageal administration of MnSOD-PL pre-irradiation results in increased engraftment of bone marrow progenitors of esophageal stem cells. Int J Radiat Oncol Biol Phys. 2007;69(3):S41–2.
Escribano A, Garcia-Grande A, Montanes P, Miralles L, Garcia A. Aerosol orgotein (Ontosein) for the prevention of radiotherapy-induced adverse effects in head and neck cancer patients : a feasibility study. Neoplasma. 2002;49(3):201–8.
Valencia J, Velilla C, Urpegui A, Alvarez I, Llorens MA, Coronel P, et al. The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori. 2002;88(5):385–9.
Epperly MW, Carpenter M, Agarwal A, Mitra P, Nie S, Greenberger JS. Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis. In Vivo. 2004;18(4):401–10.
Esco R, Valencia J, Coronel P, Carceller JA, Gimeno M, Bascon N. Efficacy of orgotein in prevention of late side effects of pelvic irradiation : a randomized study. Int J Radiat Oncol Biol Phys. 2004;60(4):1211–9.
Kadrnka F. Results of a multicenter orgotein study in radiation induced and interstitial cystitis. Eur J Rheumatol Inflamm. 1981;4(2):237–43.
Maier U, Zechner O. Therapy of radiation injuries of the bladder with orgotein (Peroxinom). J Urol Nephrol. 1988;81(5):305–8.
Menander-Huber KB, Edsmyr F, Huber W. Orgotein (superoxide dismutase): a drug for the amelioration of radiation-induced side effects. A double-blind, placebo-controlled study in patients with bladder tumors. Urol Res. 1978;6(4):255–7.
Sanchiz F, Milla A, Artola N, Julia JC, Moya LM, Pedro A, et al. Prevention of radioinduced cystitis by orgotein : a randomized study. Anticancer Res. 1996;16(4A):2025–8.
Delanian S, Martin M, Bravard A, Luccioni C, Lefaix JL. Cu/Zn superoxide dismutase modulates phenotypic changes in cultured fibroblasts from human skin with chronic radiotherapy damage. Radiother Oncol. 2001;58:325–31.
Lefaix JL, Delanian S, Leplat JJ, Tricaud Y, Martin M, Nimrod A, et al. Successful treatment of radiation-induced fibrosis using Cu/Zn SOD and Mn SOD: an experimental study. Int J Radiat Oncol Biol Phys. 1996;35(2):305–12.
Campana F, Zervoudis S, Perdereau B, Gez E, Fourquet A, Badiu C, et al. Topical superoxide dismutase reduces post-irradiation breast cancer fibrosis. J Cell Mol Med. 2004;8(1):109–16.
Delenian S, Baillet F, Huart J, Lefaix JL, Maulard C, Housset M. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide-dismutase- Clinical-Trial. Radiother Oncol. 1994;32(1):12–20.
Takehara Y, Yamaoka K, Sato EF, Yoshioka T, Utsumi K. DNA damage by various forms of active oxygens and its inhibition by different scavengers using plasmid DNA. Physiol Chem Phy Med. 1994;26(3):215–26.
Vouldoukis I, Conti M, Krauss P, Kamaté C, Blasquez S, Tefit M, et al. Supplementation with Gliadin-combined plant superoxide dismutase extract promotes antioxidant defences and protects against oxidative stress. Phytother Res. 2004;18(12):957–62.
Prost M. Utilisation de générateur de radicaux libres dans le domaine des dosages biologiques. FR Patent. 1989;2:642. 526.
Stocker P, Lesgards JF, Vidal N, Chalier F, Prost M. ESR study of a biological assay on whole blood: antioxidant efficiency of various vitamins. Biochim Biophys Acta. 2003;1621(1):1–8.
Notin C, Vallon L, Desbordes F, Leleu C. Oral supplementation with superoxide dismutase in Standardbred trotters in training: a double-blind placebo-controlled study. Eq Vet J. 2010;42(38):375–81.
Leskova GF. Protective effect of different form superoxide dismutase on the plasma membrane phospholipid composition of hepatocyte and adipocyte and on the blood lipoprotein composition in hemorrhagic shock in cats. Vopr Med Khim. 1999;45(5):389–97.
Regnault C, Roch-Arveiller M, Tissot M, Sarfati G, Giroud JP, Postaire E, et al. Effect of encapsulation on the anti-inflammatory properties of superoxide dismutase after oral administration. Clin Chim Acta. 1995;240:117–27.
Jadot G, Michelson AM, Puget K. Anti-inflammatory activity of superoxide dismutases inhibition of carrageenan induced edema in rats. Free Rad Res Comms. 1985;1(6):395–403.
Jadot G, Michelson AM, Puget K, Baret A. Anti-inflammatory activity of superoxide dismutase inhibition of Adriamycin induced edema in rats. Free Rad Res Comms. 1986;2(2):19–26.
Vaille A, Jadot G, Elizagaray A. Anti-inflammatory activity of various superoxide dismutases on polyarthritis in the Lewis rat. Biochem Pharmacol. 1990;39(2):247–55.
Gammer W, Broback LG. Clinical comparison of orgotein and methylprednisolone acetate in the treatment of osteoarthrosis of the knee joint. Scand J Rheumatol. 1984;13(2):108–12.
Goebel KM, Storck U, Neurath F. Intrasynovial orgotein therapy in rheumatoid arthritis. Lancet. 1981;1(8228):1015–7.
Lund-Olesen K, Menander-Huber KB. Intra-articular orgotein therapy in osteoarthritis of the knee. A double-blind, placebo-controlled trial. Arzneimittelforschung. 1983;33(8):1199–203.
Mazieres B, Masquelier AM, Capron MH. A French controlled multicenter study of intra-articular orgotein versus intraarticular corticosteroids in the treatment of knee osteoarthritis : a one-year followup. J Rheumatol Suppl. 1991;27:134–7.
McIlwain H, Silverfield JC, Cheatum DE, Poiley J, Taborn J, Ignaczak T, et al. Intra-articular orgotein in osteoarthritis of the knee : a placebo-controlled efficacy, safety, and dosage comparison. Am J Med. 1989;87(3):295–300.
Terlizzi N, Bonali C, Tamburrino V, Numo R. Evaluation of the efficacy of orgotein in a series of patients with hydrarthrosis of the knee. Minerva Med. 1986;77(21):947–51.
Talke M. Intra-articular therapy with superoxide dismutase (orgotein) or cortisone in rheumatoid and arthritic inflammatory finger joint lesions. Handchir Mikrochir Plast Chir. 1984;16(1):59–63.
Muller U, Moll G. Treatment of epicondylitis with locally injected orgotein (double blind study). J Rheumatol. 1983;42(1):21–4.
Lin Y, Pape HD, Friedrich R. Use of superoxide dismutase (SOD) in patients with temporomandibular joint dysfunction- a preliminary study. Int J Oral Maxillafac Surg. 1994;23(6 Pt 2):428–9.
Jadot G, Michelson AM. Comparative anti inflammatory activity of different superoxide dismutases and liposomal SOD in ischemia. Free Rad Res Comms. 1986;3(6):389–94.
Stone WC, Bjorling DE, Southard JH, Galbreath EJ, Lindsay WA. Evaluation of intestinal villus height in rats after ischemia and reperfusion by administration of superoxide-dismutase, polyethylene glycol-conjugated SOD, and 2,21-aminosteroids. Am J Vet Res. 1992;53(11):2153–6.
Segui J, Gironella M, Sans M, Granell S, Gil F, Gimeno M, et al. Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J Leukocyte Biol. 2004;76(3):537–44.
Watterlot L, Rochat T, Sokol H, Cherbuy C, Bouloufa I, Lefèvre F, et al. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol. 2010;144:35–41.
Okada F, Shionoya H, Kobayashi M, Kobayashi T, Tazawa H, Onuma K, et al. Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase. Brit J Cancer. 2006;94:854–62.
Webb CB, Lehman TL, McCord KW. Effects of an oral superoxide enzyme supplementation on indices of oxidative stress, proviral load, and CD4:CD8 ratios in asymptomatic FIV-infected cats. J Feline Med Surg. 2008;10:423–30.
Wengenack TM, Curran GL, Poduslo JF. Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia. Brain Res. 1997;754:46–54.
Nakajima S, Ohsawa I, Nagata K, Ohta S, Ohno M, Ijichi T, et al. Oral supplementation with melon superoxide dismutase extract promotes antioxidant defences in the brain and prevents stress-induced impairment of spatial memory. Behav Brain Res. 2009;200(1):15–21.
Hamm RJ, Temple MD, Pike BR, Ellis EF. The effect of postinjury administration of polyethylene glycol-conjugated superoxide dismutase (Pegorgotein, Dismutec®) or lidocaine on behavioural function following fluid-percussion brain injury in rats. J Neurotraum. 1996;13(6):325–32.
Milesi MA, Lacan D, Brosse H, Desor D, Notin C. Effect of an oral supplementation with a proprietary melon juice concentrate (Extramel®) on stress and fatigue in healthy people: a pilot, double-blind, placebo-controlled clinical trial. Nutr J. 2009;8:40.
Décordé K, Agne A, Lacan D, Ramos J, Fouret G, Ventura E, et al. Preventive effect of a melon extract rich in superoxide scavenging activity on abdominal and liver fat and adipokine imbalance in high-fat-fed hamsters. J Agric Food Chem. 2009;57:6461–7.
Décordé K, Ventura E, Lacan D, Ramos J, Cristol JP, Rouanet JM. An SOD rich melon extract Extramel® prevents aortic lipids and liver steatosis in diet-induced model of atherosclerosis. Nut Metab Card Dis. 2010;20:301–7.
Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95(3):588–93.
Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension. PNAS. 1991;88(22):10045–8.
Crapo JD, DeLong DM, Sjostrom K, Hasler GR, Drew RT. The failure of aerosolized superoxide dismutase to modify pulmonary oxygen toxicity. Am Rev Respir Dis. 1977;115:1027–33.
Freeman BA, Turrens JF, Mirza Z, Crapo JD, Young SL. Modulation of oxidant lung injury by using liposome-entrapped superoxide dismutase and catalase. Fed Proc. 1985;44:2591–5.
Padmanabhan RV, Gudapaty R, Liener IE, Schwartz BA, Hoidal JR. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am Rev Respir Dis. 1985;132:164–7.
Simonson SG, Welty-Wolf KE, Huang YC, Taylor DE, Kantrow SP, Carraway MS, et al. Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. I: physiology and biochemistry. J Appl Physiol. 1997;83:550–8.
Turrens JF, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. J Clin Invest. 1984;73:87–95.
Welty-Wolf KE, Simonson SG, Huang YC, Kantrow SP, Carraway MS, Chang LY, et al. Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. II: morphometric analysis. J Appl Physiol. 1997;83:559–68.
White CW, Jackson JH, Abuchowski A, Kazo GM, Mimmack RF, Berger EM, et al. Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. J Appl Physiol. 1989;66:584–90.
Assa’ad AH, Ballard ET, Sebastian KD, Loven DP, Boivin GP, Lierl MB. Effect of superoxide dismutase on a rabbit model of chronic allergic asthma. Ann Allergy Asthma Immunol. 1998;80:215–24.
Tanaka K, Tanaka Y, Miyazaki Y, Namba T, Sato K, Aoshiba K, et al. Therapeutic effect of lecithinized superoxide dismutase on pulmonary emphysema. J Pharmacol Exp Ther. 2011;338(3):810–8.
Rosenfeld WN, Davis JM, Parton L, Richter SE, Price A, Flaster E, et al. Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics. 1996;97(6):811–7.
Cocchia N, Pasolini MP, Mancini R, Petrazzuoto O, Cristofaro I, Rosapane I, et al. Effect of sod (superoxide dismutase) protein supplementation in semen extenders on mobility, viability, acrosome status and ERK (extracellular signal-regulated kinase) protein phosphorylation of chilled stallion spermatozoa. Theriogenology. 2011;75:1201–10.
Bartsch G, Menader-Huber KB, Huber W, Marberger H. Orgotein, a new drug for the treatment of Peyronie’s disease. Eur J Rheumatol Inflamm. 1981;4(2):250–9.
Gustafson H, Johansson B, Edsmyr F. Peyronie’s disease : experience of local treatment with Orgotein. Eur Urol. 1981;7(6):346–8.
Ludwig G. Evaluation of conservative therapeutic approaches to Peyronie’s disease (fibrotic induration of the penis). Urol Int. 1991;47(4):236–9.
Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie’s disease). Int Urol Nephrol. 1993;25(2):169–72.
Vouldoukis I, Lacan D, Kamaté C, Coste P, Calenda A, Mazier D, et al. Antioxidant and anti inflammatory properties of a cucumis melo L.C. extract rich in superoxide dismutase activity. J Ethnopharmacol. 2004;94:67–75.
Swart PJ, Hirano T, Kuipers ME, Ito Y, Smith C, Hashida M, et al. Targeting of superoxide dismutase to the liver results in anti-inflammatory effects in rats with fibrotic livers. J Hepatol. 1999;31:1034–43.
Huber W, Menander-Huber KB, Saifer MG, Williams LD. Bioavailability of superoxide dismutase: implications for the anti-inflammatory action mechanism of orgotein. Agents Actions. 1980;7:185–95.
Oyen WJ, Boerman OC, Storm G, van Bloois L, Koenders EB, Claessens RAMJ, et al. Detecting infection and inflammation with technetium-99m-labeled stealth® liposomes. J Nucl Med. 1996;37:1392–7.
Takakura Y, Masuda S, Tokuda H, Nishikawa M, Hashida M. Targeted delivery of superoxide dismutase to macrophages via mannose receptor-mediated mechanism. Biochem Pharmacol. 1994;47(5):853–8.
Giri SN, Misra HP. Fate of superoxide dismutase in mice following oral route of administration. Med Biol. 1984;62:285–9.
Zidenberg-cherr S, Keen CL, Lonnerdal B, Hurley LS. Dietary superoxide dismutase does not affect tissue levels. Am J Clin Nutr. 1983;37:5–7.
Greenwald RA. Superoxide dismutase and catalase as therapeutic agents for human diseases. A critical Review. Free Radic Biol Med. 1990;8:201–9.
Corvo ML, Boerman OC, Oyen WJG, Bloois LV, Cruz MEM, Crommelin DJA, et al. Intravenous administration of superoxide dismutase entrapped in long circulating liposomes II. In vivo fate in a rat model of adjuvant arthritis. Biochim Biophys Acta. 1999;1419:325–34.
Corvo ML, Boerman OC, Oyen WJG, Jorge JCS, Cruz MEM, Crommelin DJA, et al. Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: In vivo fate and therapeutic activity in an inflammation model. Parmaceut Res. 2000;17(5):600–6.
Jubeh TT, Antler S, Haupt S, Barenholz Y, Rubinstein A. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Molecular Pharmaceut. 2005;2(1):2–11.
Jubeh TT, Nadler-Milbauer M, Barenholz Y, Rubinstein A. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J Drug Target. 2006;14(3):155–63.
Clarke MB, Wright R, Irwin D, Bose S, Van Rheen Z, Birari R, et al. Sustained lung activity of a novel chimeric protein, SOD2/3, after intratracheal administration. Free Radic Biol Med. 2010;49:2032–9.
Arangoa MA, Campanero MA, Renedo MJ, Ponchel G, Irache JM. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharmaceut Res. 2001;18(11):1521–7.
Dugas B. Glisodin®: A nutraceutical product that promote the oral delivery of superoxide dismutase. Free Radic Biol Med. 2002;33:S64.
Carillon J, Fouret G, Feillet-Coudray C, Lacan D, Cristol JP, Rouanet JM. Short-term assessment of toxicological aspects, oxidative and inflammatory response to dietary melon superoxide dismutase in rats. Food Chem Tox. 2013;55:323–8.
Regnault C, Soursac M, Roch-arveiller M, Postaire E, Hazebroucq G. Pharmacokinetics of superoxide dismutase in rats after oral administration. Biopharm Drug Disposition. 1996;17:165–74.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 2010;49(11):1603–16.
Lallès JP, Lacan D, David JC. A melon pulp concentrate rich in superoxide dismutase reduces stress proteins along the gastrointestinal tract of pigs. Nutrition. 2011;27:358–63.
Vozenin-Brotons MC, Sivan V, Gault N, Renard C, Geffrotin C, Delanian S, et al. Antifibrotic action of Cu/Zn SOD is mediated by TGF-β1 repression and phenotypic reversion of myofibroblasts. Free Radic Biol Med. 2001;30(1):30–42.
Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM. The induction of human superoxide dismutase and catalase in vivo : A fundamentally new approach to antioxidant therapy. Free Radic Biol Med. 2006;40:341–7.
Skarpanska-Stejnborn A, Pilaczynska-Szczesniak L, Basta P, Deskur-Smielecka E, Woitas-Slubowska D, Adach Z. Effects of oral supplementation with plant superoxide dismutase extract on selected redox parameters and an inflammatory marker in a 2,000-m rowing-ergometer test. Int J Sport Nutr Exerc Metab. 2011;21(2):124–34.
Izumi M, McDonald MC, Sharpe MA, Chatteriee PK, Thiemermann C. Superoxide dismutase mimetics with catalase activity reduce the organ injury in hemorrhagic shock. Shock. 2002;18(3):230–5.
Gonzalez PK, Zhuang J, Doctrow SR, Malfroy B, Benson PF, Menconi MJ, et al. EUK-8, a synthetic superoxide dismutase and catalase mimetic, ameliorates acute lung injury in endotoxemic swine. J Pharmacol Exp Ther. 1995;275:798–806.
Yang H, Roberts LJ, Shi MJ, Zhou LC, Ballard BR, Richardson A, et al. Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E. Circ Res. 2004;95(11):1075–81.
Chan K, Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA. 1999;96(22):12731–6.
Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci USA. 2001;98(8):4611–6.
Juurlink BHJ. Dietary Nrf2 activators inhibit atherogenic processes. Atherosclerosis. 2012;225(1):29–33.
Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, et al. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol. 2008;76(11):1485–9.
Negi G, Kumar A, Joshi RP, Sharma SS. Oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle. Biochem Biophys Res Commun. 2011;408:1–5.
Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol. 2003;43:233–60.
Pedruzzi LM, Stockler-Pinto MB, Leite MJ, Mafra D. Nrf2ekeap1 system versus NF-kB: The good and the evil in chronic kidney disease? Biochimie. 2012;94(12):2461–6.
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA. 2001;98(6):3410–5.
Enwonwu CO, Sanders C. Nutrition: impact on oral and systemic health. Compend Contin Educ Dent. 2001;22:12–8.
Germano C. SOD/gliadin: the ultimate defense against disease and aging. In: Twins Streams. Kensington Publishing Corp.; 2001.pp 121–35.
Baret A, Jadot G, Michelson AM. Pharmacokinetics and anti-inflammatory properties in the rat of superoxide dismutase (CuSODs and MnSOD) from various species. Biochem Pharmacol. 1984;33(17):2755–60.
Jadot G. Anti-inflammatory activity of superoxide dismutases studies on adjuvant induced polyarthritis in rats. Free Rad Res Comms. 1985;2(2):27–42.
Michelson AM, Puget K, Jadot G. Anti-inflammatory activity of superoxide dismutases comparison of enzymes from different sources in different models in rats mechanism of action. Free Rad Res Comms. 1986;2(2):43–56.
ACKNOWLEDGMENTS AND DISCLOSURES
Julie Carillon was supported by a “CIFRE grant” (Convention Industrielle de Formation par la Recherche, n° 0417/2010) from the French “Association Nationale de la Recherche et de la Technologie” and Bionov (Avignon, France), which produces and commercializes an antioxidant product.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carillon, J., Rouanet, JM., Cristol, JP. et al. Superoxide Dismutase Administration, A Potential Therapy Against Oxidative Stress Related Diseases: Several Routes of Supplementation and Proposal of an Original Mechanism of Action. Pharm Res 30, 2718–2728 (2013). https://doi.org/10.1007/s11095-013-1113-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-013-1113-5